Novo Nordisk booked its highest annual profit in decades as the drugmaker said it is increasing access to weight-loss drug Wegovy in the United States. Accessibility statement Skip to main content.

This morning, the Danish pharmaceutical giant Novo Nordisk announced the abrupt end of its brief partnership with telehealth company Hims & Hers Health (NYSE: HIMS), citing concerns over Hims & Hers’ ...

Novo Nordisk (NVO 2.80%) has a couple of promising drugs in its portfolio that have made it a red-hot stock to own. Ozempic and Wegovy are two drugs that consumers have grown familiar with in the ...

The Danish government and the foundation behind Novo Nordisk A/S will invest €80 million ($93 million) in a Microsoft-powered ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 billion of sales worldwide.

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

As of this writing, Novo Nordisk's market cap is $468 billion, making it larger than Walmart, ExxonMobil, and Johnson & Johnson, just to name a few.. With such strong momentum fueling the company ...

Novo Nordisk A/S (NYSE:NVO) is one of the Best Extremely Profitable Stocks to Buy Right Now. On July 18, Novo Nordisk A/S ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong with when investing in for the long term. They are leade ...

Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...